Core Viewpoint - Guangzhou's Huangpu and Tianhe districts are focusing on the biopharmaceutical sector, showcasing innovative drugs and leveraging AI technology to enhance drug development efficiency [1][2][6]. Group 1: Innovative Drug Development - The innovative drug AR882 by Yipin Hong Pharmaceutical demonstrates significant efficacy in treating gout, filling a gap in oral small molecule medications [1][2]. - By 2025, China's innovative drug BD transaction scale is expected to account for 49% of the global market, with Guangzhou enterprises becoming key players in the global innovation network [2]. - Baiyoutai has achieved overseas authorization for five products totaling $750 million, with a goal of doubling annual revenue starting in 2026 and aiming for 15 global product launches by 2030 [3]. Group 2: AI Integration in Biopharmaceuticals - AI technology is becoming a crucial driver for the biopharmaceutical industry, enhancing research and production capabilities [6][7]. - Collaborations between local hospitals and AI companies aim to streamline drug discovery processes, significantly reducing the time from basic research to clinical trials [6][7]. - The global pharmaceutical AI market is projected to grow from over $4 billion in 2025 to $25.7 billion by 2030, indicating vast potential for AI in drug development [8]. Group 3: Supportive Ecosystem and Policies - The establishment of the National University Regional Technology Transfer Center in the Guangdong-Hong Kong-Macao Greater Bay Area is accelerating the transformation of research results into practical applications [5]. - Policies such as expedited approval for innovative medical devices and R&D incentives are fostering a conducive environment for biopharmaceutical innovation [4].

待建议分拆及建议上市完成后，本公司预期将拥有先声再明超过50%的权益，而先声再明将仍然为本公 司的附属公司。 先声再明为一家处于全球药物创新前沿的生物制药企业，聚焦于肿瘤创新药物的研究、开发与商业化 (不包括与细胞疗法及基因诊断与治疗技术相关的药物)。 先声药业(02096)发布公告，本公司建议分拆本公司附属公司先声再明的H股在联交所主板独立上市。先 声再明H股于联交所主板独立上市构成本公司根据第15项应用指引分拆先声再明。联交所已确认本公司 可进行建议分拆。 于2026年1月9日，先声再明就申请先声再明H股于联交所主板上市及获准买卖，向联交所递交上市申请 表格(A1表格)。按照计划，先声再明将就建议上市进行新股发售。受限于若干条件，合资格股东将可透 过在全球发售项下优先申请先声再明H股的方式，而获提供先声再明H股的保证配额。 ...

Core Viewpoint - Corning Jereh Pharmaceutical-B (09966.HK) has announced that the National Medical Products Administration of China has officially accepted the New Drug Application (NDA) for KN035 (Envafolimab injection) in combination with GEMOX for the first-line treatment of unresectable or metastatic biliary tract cancer (BTC) [1] Group 1 - The acceptance of the NDA is based on the results of a Phase III clinical trial (KN035-CN-005), which is a randomized, parallel-controlled, multi-center study designed for advanced first-line BTC patients in China [1] - The trial aims to evaluate the efficacy and safety of KN035 in combination with the GEMOX regimen compared to the GEMOX regimen alone [1] Group 2 - KN035 (Envafolimab injection) is a recombinant humanized anti-PD-L1 single-domain antibody Fc fusion protein, developed independently by the company in collaboration with Suzhou Innovent Biologics since 2016 [2] - In March 2020, a cooperation agreement was established between the company's wholly-owned subsidiary Jiangsu Corning Jereh Biopharmaceutical Co., Ltd., Jiangsu Xiansheng Pharmaceutical Co., Ltd., and Suzhou Innovent Biologics, granting Jiangsu Xiansheng exclusive marketing rights for KN035 in oncology indications in mainland China [2] - In January 2024, a licensing agreement was signed with Suzhou Innovent Biologics and Glenmark Specialty S.A., granting Glenmark exclusive licensing and sublicensing rights for KN035 in oncology indications across various regions including India, the Asia-Pacific (excluding Singapore, Thailand, and Malaysia), the Middle East and Africa, Russia, CIS countries, and Latin America [2] Group 3 - KN035 is the world's first subcutaneous PD-L1 inhibitor, which was approved by the National Medical Products Administration in November 2021 for the treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) advanced solid tumors [3]

Core Viewpoint - The company proposes to spin off its subsidiary, Xiansheng Zaiming, for an independent listing of H-shares on the Hong Kong Stock Exchange, which has been confirmed by the exchange [1] Group 1: Spin-off Details - The spin-off of Xiansheng Zaiming's H-shares will be conducted in accordance with the application guidelines of the company [1] - The company plans to submit a listing application form (A1 form) to the Hong Kong Stock Exchange on January 9, 2026, for the approval of Xiansheng Zaiming's H-shares [1] - Following the proposed spin-off and listing, the company expects to retain over 50% ownership of Xiansheng Zaiming, which will remain a subsidiary [1] Group 2: Company Profile - Xiansheng Zaiming is a biopharmaceutical company at the forefront of global drug innovation, focusing on the research, development, and commercialization of innovative oncology drugs, excluding those related to cell therapy and gene diagnosis and treatment technologies [1]

证券日报网讯 1月9日，爱美客在互动平台回答投资者提问时表示，公司美格鲁肽注射液项目目前处于 临床试验阶段。公司研发项目相关情况可查阅公司《2025年半年度报告》中"研发项目进展"部分。 （文章来源：证券日报） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 關於KN035（恩沃利單抗注射液）（商標名：恩維達®） KN035（恩沃利單抗注射液）是重組人源化抗程序性死亡配體1（「PD-L1」）單域 抗體Fc融合蛋白，由本公司自主研發，2016年起與思路迪（北京）醫藥科技有限 公司（「思路迪醫藥」）合作開發。於2020年3月30日，本公司全資附屬公司江蘇 康寧傑瑞生物製藥有限公司（「江蘇康寧傑瑞」）、江蘇先聲藥業有限公司（「江蘇 先聲」，為先聲藥業集團有限公司（其股份於聯交所上市，股份代號：2096）的 附屬公司）及思路迪醫藥訂立一份合作協議（「先聲協議」）。根據先聲協議，江蘇 先聲獲授予KN035於中國大陸內的腫瘤適應症的獨家市場推廣權及對外許可或 轉讓下的優先受讓權。於2024年1月，我們與思路迪醫藥及Glenmark Specialty S.A.（「Glenmark」）訂立許可協議，據此思路迪醫藥與本集團同意向Glenmark授 予KN035腫瘤適應症的獨 ...

Core Viewpoint - Changchun High-tech has over 40 candidate drugs in clinical stages or submitted for IND applications, with significant advancements in its pipeline expected by late 2025 [2] Group 1 - As of the last feasible date of the company's prospectus (late September 2025), it has more than 40 candidate drugs in clinical stages or submitted for IND applications [2] - Among these, there are 14 candidates in Phase III clinical trials or new drug application (NDA) stages, and 15 first-class innovative drugs [2] - The company advises stakeholders to refer to its subsequent annual reports for accurate disclosures by the end of 2025 and to check previous announcements for recent clinical progress of key innovative products [2]

Core Insights - The pharmaceutical industry is experiencing a significant shift in sentiment as executives prepare for the upcoming J.P. Morgan Healthcare Conference, with a more relaxed attitude compared to 2025 [1] - Concerns regarding drug pricing policies and tariffs that could erode profits have largely dissipated, leading to a notable reduction in industry anxiety [1][3] - Biopharmaceutical transactions have more than doubled over the past year, with expectations for continued growth in 2026 [1][3] Group 1 - The J.P. Morgan Healthcare Conference serves as a key networking and deal-making event for thousands of biopharmaceutical executives and investors [3] - A recent agreement with the White House aimed at lowering drug prices has positively influenced market sentiment, as companies have not significantly adjusted their financial outlooks [3] - In 2025, pharmaceutical companies completed $130 billion in transactions, a 124% increase from the previous year, with approximately 30 deals exceeding $1 billion [3] Group 2 - Major pharmaceutical companies like Merck, Pfizer, and Bristol-Myers Squibb are under pressure to replenish their product pipelines as blockbuster drug patents expire in the next five years, threatening over $300 billion in sales [6] - The rising stock prices have emboldened CEOs to pursue mergers and acquisitions, leading to competitive bidding wars for biotech firms developing potential blockbuster drugs [6][7] - Mid-sized companies are also actively acquiring early-stage biotech firms, indicating a shift in strategy as they seek growth opportunities [7] Group 3 - Despite the optimism, rising valuations may deter potential buyers from pursuing acquisitions [7] - Political uncertainties remain, particularly with the Trump administration's influence on the FDA and its unpredictable leadership changes [8] - The FDA has recently rejected several rare disease drug applications, causing frustration among investors and advocacy groups, which may lead to a more cautious approach to major mergers [8]

（编辑 楚丽君） 证券日报网讯 1月9日，智飞生物在互动平台回答投资者提问时表示，关于公司控股股东部分股份解除 质押的事项已于2026年1月5日披露于证监会指定的信息披露网站，详见《关于公司控股股东部分股份解 除质押的公告》（2026-03）。 ...

证券日报网讯 1月9日，智飞生物在互动平台回答投资者提问时表示，公司严格按照法律法规履行信息 披露义务。公司持续优化经营策略，加速推进自研产品上市，强化市场宣传推广，促进公司稳健发展。 （文章来源：证券日报） ...